# Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

> **NCT02581657** · PHASE2 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 37 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** PE0139 Injection
- **DRUG:** Placebo Injection

## Key facts

- **NCT ID:** NCT02581657
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581657, "Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02581657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*